# US 2020/0002330 A1 · Compounds and compositions for inhibiting the activity of shp2

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0002330 A1
- Document ID: US20200002330A1
- Status: Published application
- Kind: A1
- Application number: 16/309,076
- Filed: 2017-06-12
- Published: 2020-01-02
- Earliest claimed: 2016-06-14
- Assignees: Novartis AG
- Applicants: Novartis AG
- Inventors: Zhuoliang CHEN; Jorge Garcia FORTANET; Rajesh KARKI; Matthew J. LAMARCHE; Dyuti MAJUMDAR; Lawrence Blas PEREZ; Martin SENDZIK; Troy Douglas SMITH; Fan YANG; Bing YU
- Web page: https://patentgrep.com/patent/US20200002330A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 401/14: containing three or more hetero rings
- C07D 403/14: containing three or more hetero rings
- C07D 455/02: containing not further condensed quinolizine ring systems
- C07D 487/04: Ortho-condensed systems
- C07D 495/04: Ortho-condensed systems
- C07D 513/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compounds of formula I: in which Y1, Y2, R1, R2 and R3 are defined in the Summary of the Invention; capable of inhibiting the activity of SHP2. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds and compositions in the management of diseases or disorders associated with the aberrant activity of SHP2.

## Claims

### Claim 1

A compound selected from formula I and II:
in which:
R1 is selected from:
R2 and R3 together with the nitrogen to which both R2 and R3 are attached form a ring selected from piperidinyl, piperazinyl, 2-oxa-8-azaspiro[4.5]decan-8-yl, 8-azaspiro[4.5]decan-8-yl and pyrrolidinyl; wherein said pyrrolidinyl, piperazinyl, 2-oxa-8-azaspiro[4.5]decan-8-yl, 8-azaspiro[4.5]decan-8-yl or piperidinyl is unsubstituted or substituted with 1 to 3 groups independently selected from amino, methyl, ethyl, amino-methyl, methyl-amino, hydroxyl, cyano, fluoro-methyl, fluoro and ((((5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy)carbonyl)amino)methyl;
R4 is selected from hydroxyl, C1-3alkoxy and OC(O)C1-3alkyl;
R5 is selected from H and methyl;
R6 is selected from hydrogen, methyl and phenyl;
R7 is selected from hydrogen, methyl, ethyl, phenyl and benzyl;
R8 is selected from hydrogen and methyl;
Y1 is selected from N and CH;
Y2 is selected from N and CH;
Y3 is selected from NH and CH2;
Y4 is selected from N and CH;
Y5 is selected from N and CH; or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1 of formula II:
in which:
R1 is selected from:
R2 and R3 together with the nitrogen to which both R2 and R3 are attached form a ring selected from piperidinyl, piperazinyl, 2-oxa-8-azaspiro[4.5]decan-8-yl, 8-azaspiro[4.5]decan-8-yl and pyrrolidinyl; wherein said pyrrolidinyl, piperazinyl, 2-oxa-8-azaspiro[4.5]decan-8-yl, 8-azaspiro[4.5]decan-8-yl or piperidinyl is unsubstituted or substituted with 1 to 3 groups independently selected from amino, methyl, ethyl, amino-methyl, methyl-amino, hydroxyl, cyano, fluoro-methyl, fluoro and ((((5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy)carbonyl)amino)methyl;
R4 is selected from hydroxyl;
R5 is selected from H and methyl;
R6 is selected from hydrogen, methyl and phenyl;
R7 is selected from hydrogen, methyl, ethyl, phenyl and benzyl;
R8 is selected from hydrogen and methyl;
Y1 is selected from N and CH;
Y2 is selected from N and CH;
Y3 is selected from NH and CH2;
Y4 is selected from N and CH;
Y5 is selected from N and CH; or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 2)

The compound of claim 2, or the pharmaceutically acceptable salt thereof, in which:
R1 is selected from:
R4 is selected from hydroxyl;
R5 is selected from H and methyl;
R6 is selected from hydrogen, methyl and phenyl;
R7 is selected from hydrogen, methyl, ethyl, phenyl and benzyl;
R8 is selected from hydrogen and methyl;
Y4 is selected from N and CH; and
Y5 is selected from N and CH.

### Claim 4 (depends on 3)

The compound of claim 3, or the pharmaceutically acceptable salt thereof, selected from:

### Claim 5 (depends on 1)

The compound of claim 1 of formula I:
in which:
R1 is selected from:
R2 and R3 together with the nitrogen to which both R2 and R3 are attached form a ring selected from piperidinyl, piperazinyl, 2-oxa-8-azaspiro[4.5]decan-8-yl, 8-azaspiro[4.5]decan-8-yl and pyrrolidinyl; wherein said pyrrolidinyl, piperazinyl, 2-oxa-8-azaspiro[4.5]decan-8-yl, 8-azaspiro[4.5]decan-8-yl or piperidinyl is unsubstituted or substituted with 1 to 3 groups independently selected from amino, methyl, ethyl, amino-methyl, methyl-amino, hydroxyl, cyano, fluoro-methyl, fluoro and ((((5-methyl-2-oxo-1,3-dioxol-4-yl)methoxy)carbonyl)amino)methyl;
R4 is selected from hydroxyl;
R5 is selected from H and methyl;
R6 is selected from hydrogen, methyl and phenyl;
R7 is selected from hydrogen, methyl, ethyl, phenyl and benzyl;
R8 is selected from hydrogen and methyl;
Y1 is selected from N and CH;
Y2 is selected from N and CH;
Y3 is selected from NH and CH2;
Y4 is selected from N and CH;
Y5 is selected from N and CH; or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 5)

The compound of claim 5, or the pharmaceutically acceptable salt thereof, selected from:

### Claim 7 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier.

### Claim 8 (depends on 1)

A method of treatment comprising administering a compound of claim 1, or a pharmaceutically acceptable salt thereof, to a person in need of such treatment in an effective amount for the prophylactic or therapeutic treatment of a disease or disorder which is mediated by the activity of SHP2.

### Claim 9 (depends on 8)

The method of claim 8, wherein the disease or disorder mediated by the activity of SHP2 is selected from Noonan Syndrome, Leopard Syndrome, juvenile myelomonocytic leukemias, neuroblastoma, melanoma, acute myeloid leukemia, breast cancer, esophageal cancer, lung cancer, colon cancer, head cancer, neuroblastoma, squamous-cell carcinoma of the head and neck, gastric carcinoma, anaplastic large-cell lymphoma and glioblastoma.
